Prevention of cervical cancer with vaccines

Current Oncology Reports

Volumn 3, Issue 4, 2001, Pages 322-328

  Im, Samuel S ^a   Monk, Bradley J ^a   Villarreal, Luis P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Central Etiologic Factor; Cervical Cancer; Peptide Vaccine; Vulvar Intraepithelial Neoplasia

Indexed keywords

VIRUS VACCINE;

ANIMAL; CLINICAL TRIAL; FEMALE; HUMAN; IMMUNOLOGY; PAPILLOMA VIRUS; REVIEW; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ANIMALS; CLINICAL TRIALS; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0035406502     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-001-0084-6     Document Type: Article

References (50)

1. Murakami M, Gurski KJ, Steller MA: Human papillomavirus vaccines for cervical cancer. J Immunother 1999, 22:212–218.
2. Parkin DM, Pisani P, Ferlay J: Estimates of worldwide incidence from 25 major cancers in 1990. Int J Cancer 1999, 80:827–841.
3. Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999, 83:18–29.
4. Walboomers JM, Jacobs MV, Manos MM, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12–19.
5. Stoler MH: Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Path 2000, 19:16–28.
6. Dupuy C, Buzoni-Gatel D, Touze A, et al.: Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 1999, 73:9063–9071. Intranasally administered VLP vaccine induced both humoral and cellular immune response in murine vaginal epithelia.
7. Bosch FX, Manos MM, Munoz N, et al.: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995, 87:796–802.
8. Human papillomaviruses: a compilation and analysis of nucleic acid and amino acid sequences. In Human Papillomaviruses 1996 Compendium: Glossary and Landmarks. Los Alamos, NM: Los Alamos National Laboratory; 1996:v-vi.
9. Scheffner M, Werness BA, Huibregtse JM, et al.: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129–1136.
10. Nead MA, McCance DJ: Activities of the transforming proteins of human papillomaviruses. In Human Tumor Viruses. Edited by McCance DJ. Washington, DC: American Society for Microbiology Press; 1998:225–251.
11. Gissman L: Human papillomaviruses and genital cancer. Semin Cancer Biol 1992, 3:253.
12. Schiller JT, Hidesheim A: Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol 2000, 19:67–74.
13. Stern PL, Brown M, Stacey SN, et al.: Natural HPV immunity and vaccination strategies. J Clin Virol 2000, 19:57–66.
14. zur Hausen H: Yohei Ito memorial lecture: papillomaviruses in human cancers. Leukemia 1999, 13:1–5.
15. af-Geijersstam V, Eklund C, Wang Z, et al.: A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. Int J Cancer 1999, 80:489–493.
16. Lutzner MA: Papillomavirus lesions in immunodepression and immunosuppression. Clin Dermatol 1985, 3:165–169.
17. Garzetti GG, Ciavattini A, Buttini L, et al.: Cervical dysplasia in HIV-seropositive women: role of human papillomavirus infection and immune status. Gynecol Obstet Invest 1994, 40:52–56.
18. Petry KU, Scheffel D, Bode U, et al.: Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 1994, 57:836–840.
19. Ozsaran AA, Ates T, Dikmen Y, et al.: Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Eur J Gynaecol Oncol 1999, 20:127–130.
20. Kirnbauer R, Booy F, Cheng N, et al.: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992, 89:12180–12184.
21. Rose RC, Reichman RC, Bonnez W: Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994, 75:2075–2079.
22. Pilacinski WP, Glassman DL, Glassman KF, et al.: Immunization against bovine papillomavirus infection. In Papillomaviruses: Ciba Foundation Symposium. Chichester: Wiley; 1986:136–156.
23. Christensen ND, Kreider JW, Kan NC, DiAngelo SL: The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 1991, 181:572–579.
24. Breitburd F, Kirnbauer R, Hubbert NL, et al.: Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995, 69:3959–3963.
25. Christensen ND, Reed CA, Cladel NM, et al.: Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomaviruses. J Virol 1996, 70:960–965.
26. Suzich JA, Ghim S, Palmer-Hill FJ, et al.: Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995, 92:11553–11557.
27. Kirnbauer R, Chandrachud L, O’Neil B, et al.: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996, 219:37–44.
28. Nardelli-Haefliger D, Roden RBS, Benyacoub J, et al.: Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997, 65:3328–3336.
29. Revaz V, Benyacoub J, Kast WM, et al.: Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV 16) L1 virus-like particles (VLPs) or HPV 16 VLPs purified from insect cells inhibits the growth of HPV 16-expressing tumor cells in mice. Virology 2001, 279:354–360.
30. Rudolf MP, Nieland JD, DaSilva DM, et al.: Induction of HPV 16 capsid protein-specific human T cell responses by viruslike particles. Biol Chem 1999, 380:335–340.
31. Harro CD, Pang YYS, Roden RBS, et al.: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001, 93:284–292. Report on the first double-blinded, randomized phase I VLP prophylactic vaccine trial in humans. In vaccinated human subjects, HPV-16-specific serum antibody titer increased by 40-fold compared with those who were naturally seroconverted.
32. Borysiewics LK, Fiander A, Nimako M, et al.: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347:1523–1527.
33. Steller MA, Gurski KJ, Murakami M, et al.: Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998, 4:2103–2109.
34. van Driel WJ, Ressing ME, Kenter GG, et al.: Vaccination with HPV 16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999, 35:946–952.
35. Ressing ME, van Driel WJ, Brandt RM, et al.: Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000, 23:255–266.
36. Muderspach L, Wilczynski S, Roman L, et al.: A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000, 6:3406–3416.
37. Shi W, Bu P, Liu J, et al.: Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol 1999, 73:7877–7881.
38. Suzue K, Young RA: Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol 1996, 156:873–879.
39. Chen CH, Wang TL, Hung CF, et al.: Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000, 60:1035–1042. A report on the fusion of HPV E7 and hsp 70 enhanced DNA vaccine potency.
40. Liu DW, Tsao YP, Kung JT, et al.: Recombinant adenoassociated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 2000, 74:2888–2894. Use of a viral vaccine vector for fused HPV E7 and hsp 70 primed both the cellular and humoral immune response.
41. Chu NR, Wu HB, Wu T, et al.: Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV 16 E7. Clin Exp Immunol 2000, 121:216–225.
42. Ji H, Wang TL, Chen CH, et al.: Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 1999, 10:2727–2740. Rerouting the HPV tumor antigen into the endosomal/lysosomal compartment enhanced the potency of this DNA vaccine.
43. Wang TL, Ling M, Shih IM, et al.: Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 2000, 7:726–733. E7-transfected dendritic cells were effective as vaccines in eliciting both humoral and cellular immune response in a murine model.
44. de Bruijn MLH, Schuurhuis DH, Vierboom MPM, et al.: Immunization with human papillomavirus type 16 (HPV 16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV 16-induced tumor cells. Cancer Res 1998, 58:724–731. Dendritic cells pulsed with HPV-16 E7 were used as a vaccine in a murine model. The vaccinated mice showed enhanced tumor protection.
45. Lee AH, Suh YS, Sung YC: DNA inoculations with HIV-1 recombinant genomes that express cytokine genes enhance HIV-1 specific immune responses. Vaccine 1999, 17:473–479.
46. Lee SW, Cho JH, Sung YC: Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol 1998, 72:8430–8436.
47. Chang EY, Chen CH, Ji H, et al.: Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 2000, 86:725–730. A fused vaccine with HPV E7 and GM-CSF, which stimulates the maturation of dendritic cells, showed both increased cellular immune response and antitumor activity.
48. Hung CF, Hsu KF, Cheng WF, et al.: Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 2001, 61:1080–1088. Linkage of HPV E7 with the extracellular domain of FL, which is capable of a growth-stimulatory effect on the dendritic cells, showed enhanced DNA vaccine potency.
49. Greenstone HL, Nieland JD, de Visser KE, et al.: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV 16 tumor model. Proc Natl Acad Sci U S A 1998, 95:1800–1805. Chimeric VLP with HPV early protein fused to the L2 capsid protein appears to elicit both humoral and cellular immune response.
50. Jochmus I, Schafer K, Faath S, et al.: Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 1999, 30:269–274.